CHIMERIC THERAPEUTICS

APPENDIX 4C

Quarter Ended 30 June 2026

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **31 July 2026**

QUARTERLY ACTIVITIES & CASHFLOW REPORT
QUARTER ENDING 30 JUNE 2026

Sydney, Australia, 31 July 2026: Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to provide a summary of its activities for the quarter ended 30 June 2026 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

Highlights

- **Phase 1 study continues to progress with 9 of 11 evaluable patients treated with CHM CDH17 including four patients treated at Dose Level 3 of 450 million CAR-T cells**
- **Phase 1 interim data from two patients at Dose Level 3; tumour shrinkage from 17% to 40% in individual lesions and stable disease maintained for 6 months and 4 months respectively**
- **Phase 1 data poster presentation at ASCO 2026 in Chicago**
- **60% of enrolled patients in ADVENT-AML Phase 1B trial of CHM CORE-NK trial achieve complete response or complete response with incomplete count recovery**
- **Strategic Review commenced on 1 July 2026 to realise and maximise value for Chimeric assets**
- **Closing Cash of $0.8M at 30 June 2026 – additional $2.27M received in July 2026**

Dr Rebecca McQualter, CEO of Chimeric commented:

"This Quarter we have continued to make strong clinical progress in our lead program with CHM CDH17 with the study moving to dose level 3. The interim data we reported last week is positive and while the sample is small, it is pleasing to see some tumours shrinking up to 40% and also ongoing presence of CAR-T in these patients. We look forward to treating our next patient shortly and reading out additional data. We aim to complete the study with the final patient later this year, subject to our funding."

Clinical Trial Updates

Positive Phase 1/2 CHM CDH17 data presented at ASCO

Chimeric announced positive clinical and translational data from the Phase 1/2 trial of CHM CDH17, its first-in-class, third-generation autologous CAR T cell therapy targeting CDH17, a cancer biomarker associated with poor prognosis and metastases in common gastrointestinal tumours. The data were presented at the American Society of Clinical Oncology (**ASCO**) in the United States and related to the ongoing Phase 1/2 study in patients with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours.

As at the 12 May 2026 data cut-off, 16 subjects had been enrolled, with two screen failures and 12 patients treated to date across Dose Levels 1, 2 and 3. Chimeric reported a 100% successful manufacturing rate for CHM CDH17, supporting treatment of the enrolled patients. Of 11 evaluable patients, nine achieved stable disease per RECIST, representing a disease control rate of 82%. This included one patient maintaining stable disease for more than 15 months and another for 12 months, with three patients remaining on study at the time of reporting.

The ASCO data also showed that, following infusion, CHM CDH17 expanded and persisted in the peripheral blood of all treated patients, with pharmacokinetic data suggesting robust expansion and persistence beyond 30 days and persistence observed for up to 15 months to date. The Company noted that these findings significantly de-risk the asset by demonstrating cellular expansion and persistence across all treated patients.

CHM CDH17 was reported to be tolerable in heavily pre-treated metastatic cancer patients, with evidence of disease control. There was one dose-limiting toxicity. Grade 3 treatment-related adverse events included cytokine release syndrome, enterocolitis, neutropenic fever and fatigue, all of which resolved. No grade 4 or grade 5 treatment-related adverse events were reported. Treatment-emergent adverse events of grade 4 were associated with lymphodepletion prior to receiving therapy, which the Company noted is consistent with toxicities documented across cell therapy treatments.

CEO Dr Rebecca McQualter hosted an investor webinar to discuss the data. A replay of the webinar is available at: https://youtu.be/itLbe_g29qs?si=2tR6hOuzVfBf3x7V

New interim data from Dose Level 3 patients in Phase 1/2 CHM CDH17 study

Subsequent to the end of the Quarter, the Company provided a further clinical update from the Phase 1/2 CHM CDH17 study with four patients having been treated at Dose Level 3 (450 million CAR-T cells).

The new preliminary data received for two Dose Level 3 patients shows tumour shrinkage ranging from 17% to 40% in individual lesions. One patient has maintained Stable Disease for six months, and another for four months, as assessed under RECIST 1.1 criteria.

These results extend the interim data reported to the ASX on 31 May 2026, which described 82% disease control at the 28-day assessment (9 of 11 evaluable patients) and one dose limiting toxicity. Further data from the remaining two patients to be reported as it becomes available.

CHM CORE-NK Phase 1B Clinical Trial Achieves 60% CR/CRi

In April 2026, Chimeric announced clinical data from the ADVENT-AML Phase 1B trial of CHM CORE-NK in combination with azacitidine and venetoclax in high-risk, frontline acute myeloid leukemia patients.

Of the 25 patients enrolled, 60% achieved a complete response or complete response with incomplete count recovery (CR/CRi), compared with a typical 20–30% response rate for current standard of care in this high-risk patient population. The treatment continued to be well tolerated, with no unexpected safety findings reported. The investigator-initiated trial remains open at The University of Texas MD Anderson

Cancer Center and is enrolling up to three additional newly diagnosed AML patients who are not eligible for intensive chemotherapy or allogeneic stem cell transplant. Translational data, including persistence and cytokine profiles, are currently being evaluated.

Corporate Updates

Completion of Capital Consolidation

During the Quarter, the consolidation of the Company's issued capital on a 1 for 100 basis, as set out in the Notice of Extraordinary General Meeting dated 19 March 2026 and approved by shareholders at the Meeting on 17 April 2026, was completed.

The Company's post consolidation capital structure is set out below as at 29 April 2026:

ASX code	Description	Number on issue	
Quoted securities		**Pre-consolidation**	**Post consolidation**
CHM	ORDINARY FULLY PAID	4,418,703,619	44,187,956
Unquoted securities			
CHMAY	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	303,254,331	3,032,569
CHMAAH	OPTION EXPIRING 10-OCT-2028 EX $0.80*	25,000,000	250,000
CHMAAB	PERFORMANCE RIGHTS	7,227,904	72,280

** Option exercise price shown post consolidation*

Board update

Subsequent to the end of the Quarter, Independent Non-Executive Director Mr Eric Sullivan notified the Board of his decision to retire from the Board. Mr Sullivan joined the Chimeric Board in August 2023 and during his tenure served as Chairman of the Audit and Risk Committee and as a Member of the Remuneration and Compensation Committee. Mr Sullivan has resigned for personal reasons and accordingly this will take effect immediately. The full Board will now perform the function of the Audit and Risk Committee until further notice.

Appointment of Independent Financial Adviser for Strategic Review

Also following the end of the Quarter, Chimeric appointed Hawkesbury Partners as independent financial adviser to undertake a structured review of the strategic options available to the Company, as the Board believes the intrinsic value of the Company's portfolio and assets is not currently reflected in the Company's market capitalisation.

The scope of the strategic review includes identifying and evaluating opportunities to realise and maximise value for Chimeric and its assets. This may include strategic partnerships and funding, licensing arrangements, co-development agreements, mergers, asset sale transactions and alternative capital structures. The Company is actively reviewing all strategic and funding options and there are a number of ongoing discussions. There is no certainty any transaction will result from the process and the Company will update the market on material developments in accordance with its continuous disclosure obligations.

Financial Matters

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

As detailed in the attached ASX Appendix 4C, the Company had $0.80 million in cash and cash equivalents at 30 June 2026, decreasing from $1.75 million at the end of the prior Quarter. An additional $2.27 million was received in July 2026.

The net cash outflow in Operating Activities during the Quarter was $3.53 million with 87% of operating activities relates to staff costs and research and development expenditure associated on supporting Phase 1/2 of the CHM CDH17 trial as detailed in the Appendix 4C. As the study is nearing completion of enrolment it is expected that that expenditure will decrease in the coming Quarters.

The net financing inflows for the Quarter was $2.57 million which consists of $2.09 million received as part of the April Placement and $0.75 million received from issue of convertible debt securities less transaction costs.

Subsequent to 30 June 2026, the Company drew a further $0.65 million from it's convertible note facility, and also secured a $1.62 million R&D Advance from Endpoints Capital under a funding facility secured against Chimeric's FY26 Research and Development Tax incentive. The funding received during July will support the ongoing Phase 1/2 clinical trial activities and general working capacity.

In accordance with Listing Rule 4.7C, payments made to related parties and their associated included in items 6.1 of the Appendix 4C include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses. The Board has focused on prudent management of cash and as a result careful cost cutting strategy projected total expenditure has and will continue to be reduced.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated.

For more information visit **www.chimerictherapeutics.com** or follow us on LinkedIn at **www.linkedin.com/company/chimeric-therapeutics.**

Contact

Investors
Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Chimeric Therapeutics Limited

ABN	**Quarter ended ("current quarter")**
68 638 835 828	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	-	-
1.2	Payments for (inclusive of GST)		
	(a) research and development	(2,501)	(9,935)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(577)	(3,496)
	(f) administration and corporate costs	(502)	(2,004)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	4	40
1.5	Interest and other costs of finance paid	-	(107)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	4,498
1.8	Other (provide details if material)	46	220
1.9	**Net cash from / (used in) operating activities**	**(3,530)**	**(10,784)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Payments of license fee liabilities)	-	(249)
2.6	**Net cash from / (used in) investing activities**	**-**	**(249)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	2,086	8,793
3.2	Proceeds from issue of convertible debt securities	750	750
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(268)	(896)
3.5	Proceeds from borrowings	-	1,785
3.6	Repayment of borrowings	-	(2,500)
3.7	Transaction costs related to loans and borrowings	-	(185)
3.8	Dividends paid	-	-
3.9	Other – repayment of debt facility	-	(1,665)
3.10	**Net cash from / (used in) financing activities**	**2,568**	**6,082**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,750	5,757
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,530)	(10,784)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(249)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,568	6,082
4.5	Effect of movement in exchange rates on cash held	12	(6)
4.6	**Cash and cash equivalents at end of period**	**800**	**800**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	800	1,750
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**800**	**1,750**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	63
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,530)
8.2	Cash and cash equivalents at quarter end (item 4.6)	800
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**800**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.23

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: The Company does not expect to continue to have a similar level of net operating cash flows and will continue to reduce its discretionary operational activities to preserve available cash.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

The Board continues to actively assess a range of funding alternatives to support the Company's ongoing operations. The Directors remain confident that sufficient capital can be secured through a combination of equity financing and non-dilutive funding sources.

In addition, the Company has secured commitments of $4.0 million (before costs) under a convertible note facility and associated warrants, available for drawdown during the quarter.

Subsequent to 30 June 2026, the Company received an additional $2.27M from a further $0.65 million from it's convertible note facility, and also secured a $1.62 million R&D Advance from Endpoints Capital under a funding facility secured against Chimeric's FY26 Research and Development Tax incentive. The funding received during July will support the ongoing Phase 1/2 clinical trial activities and general working capacity.

The Company has implemented, and will continue to pursue, prudent cash management initiatives, including the deferral of discretionary expenditure and operational activities where appropriate, to preserve liquidity and extend its available cash runway.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:
Yes, the Board expects to be able to continue its operations and to meet its business objectives based on the responses detailed in 8.6.1 and 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

CHIMERIC
THERAPEUTICS

+61 3 9824 5254
info@chimerictherapeutics.com

Chimeric Therapeutics Limited
ACN 638 835 828

ASX: CHM